Multiple Myeloma Coverage from Every Angle

DREAMM-2: Sustained Activity Reported With Belantamab Mafodotin-blmf in Resistant Myeloma

By: Celeste L. Dixon
Posted: Thursday, September 9, 2021

“Belantamab mafodotin-blmf has the potential to shift the treatment paradigm in the heavily pretreated, anti-CD38 monoclonal antibody–exposed [relapsed or refractory multiple myeloma] patient population, [who have] a poor prognosis and few alternative treatment options,” declared Adam D. Cohen, MD, of Abramson Cancer Center, Philadelphia, and colleagues in the journal Cancer, based on their 13-month follow-up investigating longer-term efficacy and safety outcomes in the ongoing phase II DREAMM-2 study. Of note, this patient population includes those with high-risk cytogenetics and renal impairment. Single-agent belantamab mafodotin was approved by the U.S. Food and Drug Administration based on earlier DREAMM-2 results in this patient population who had received at least four prior therapies, including anti-CD38 therapy.

The extended analysis revealed a median estimated overall survival of 13.7 months in patients taking single-agent belantamab mafodotin at 2.5 mg/kg, “substantially longer than that reported in a similar population,” Dr. Cohen and co-investigators wrote. The median estimated durations of response in the overall 2.5-mg/kg group—11 months—and in patients who achieved a minimal response or better—11.7 months—are the longest reported to date in patients with triple-class–refractory multiple myeloma, they noted.

Of note, of the patients who had a clinical response and then prolonged dose delays of more than 2 months, mostly because of corneal adverse effects, 88% maintained or deepened responses during their first prolonged dose delay. Further, no new safety signals were identified during this follow-up, and the follow-up continues for long-term responders.

Disclosure: The study authors’ disclosure information can be found at

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.